# OnCo record lenvatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lenvatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lenvatinib" ;
  schema:name "Lenvatinib"@en ;
  schema:description "An oral anti-angiogenic pill that matched sorafenib in liver cancer with higher response rates, and partners with pembrolizumab in kidney and endometrial cancer."@en ;
  schema:url <https://onco.cc/drugs/lenvatinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lenvatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q6523413> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lenvatinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)" ;
  schema:alternateName "Lenvima" ;
  onco:approval "US 2015: Radioiodine-refractory thyroid cancer", "US 2018: First-line unresectable HCC", "US 2021: Advanced RCC with pembrolizumab; endometrial cancer with pembrolizumab", "US 2016: Advanced RCC with everolimus after anti-angiogenic therapy" ;
  onco:acceleratedApproval "US 2019-09-17: In combination with pembrolizumab for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation" ;
  onco:acceleratedApprovalConfirmed "US 2021-07-21: In combination with pembrolizumab for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation" ;
  onco:related <https://onco.cc/biomarkers/msi-high/> ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-advanced/>, <https://onco.cc/cancers/hcc-intermediate/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/papillary-thyroid-cancer/>, <https://onco.cc/cancers/follicular-thyroid-cancer/>, <https://onco.cc/cancers/anaplastic-thyroid-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/kit/> ;
  onco:companies <https://onco.cc/companies/eisai/>, <https://onco.cc/companies/merck/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:terms <https://onco.cc/terms/tace-term/> ;
  onco:trials <https://onco.cc/trials/reflect/>, <https://onco.cc/trials/leap-002/>, <https://onco.cc/trials/leap-012/>, <https://onco.cc/trials/nct04194775/>, <https://onco.cc/trials/nct06371157/>, <https://onco.cc/trials/nct05822752/>, <https://onco.cc/trials/nct05775159/>, <https://onco.cc/trials/nct07219459/>, <https://onco.cc/trials/nct07081633/>, <https://onco.cc/trials/nct05112991/>, <https://onco.cc/trials/nct05024214/>, <https://onco.cc/trials/nct02861573/>, <https://onco.cc/trials/nct05903833/>, <https://onco.cc/trials/nct04977453/>, <https://onco.cc/trials/nct04008797/>, <https://onco.cc/trials/nct04626479/>, <https://onco.cc/trials/nct05319730/>, <https://onco.cc/trials/nct04586231/>, <https://onco.cc/trials/nct05899049/>, <https://onco.cc/trials/nct04938817/>, <https://onco.cc/trials/nct04976634/>, <https://onco.cc/trials/nct04626518/>, <https://onco.cc/trials/nct06682780/>, <https://onco.cc/trials/nct07405164/>, <https://onco.cc/trials/nct06962787/>, <https://onco.cc/trials/clear/>, <https://onco.cc/trials/litespark-012/>, <https://onco.cc/trials/keynote-775/> .